Nikko Asset Management Americas, Inc. 13D and 13G filings for CRISPR Therapeutics AG:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-12 6:22 pm Sale |
2023-12-31 | 13G | CRISPR Therapeutics AG CRSP |
Nikko Asset Management Americas, Inc. | 3,369,762 4.240% |
-636,714 (-15.89%) |
Filing |
| 2023-02-10 10:30 am Sale |
2022-12-31 | 13G | CRISPR Therapeutics AG CRSP |
Nikko Asset Management Americas, Inc. | 4,006,476 5.110% |
-312,995 (-7.25%) |
Filing |
| 2022-02-14 06:05 am Purchase |
2021-12-31 | 13G | CRISPR Therapeutics AG CRSP |
Nikko Asset Management Americas, Inc. | 4,319,471 5.640% |
482,648 (+12.58%) |
Filing |
| 2021-02-11 5:14 pm Purchase |
2020-12-31 | 13G | CRISPR Therapeutics AG CRSP |
Nikko Asset Management Americas, Inc. | 3,836,823 5.390% |
787,270 (+25.82%) |
Filing |